PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Neeraj Agarwal

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

Nobuaki Matsubara

National Cancer Center Hospital East, Chiba, Japan

Arun A. Azad

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Fred Saad

Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal

Joaquin Mateo

Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona

Shusuan Jiang

Hunan Cancer Hospital, Changsha, China

Dingwei Ye

Fudan University Shanghai Cancer Center, Shanghai

Eric Voog

Clinique Victor Hugo, Centre Jean Bernard, Le Mans, France

Neal D. Shore

START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC

Timuçin Çil

Adana City Education and Research Hospital, Adana Faculty of Medicine, University of Health Sciences, Adana, Turkey

Christof Vulsteke

Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, Belgium

Hsiao-Jen Chung

Taipei Veterans General Hospital, Taipei, Taiwan

Stefanie Zschäbitz

Department of Medical Oncology, Heidelberg University Hospital, and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany

A. Douglas Laird

Pfizer, South San Francisco, CA

Xiaoxi Zhang

Pfizer, New York

Prachi Nandoskar

Pfizer, South San Francisco, CA

Sarah Fenech Chetcuti

Pfizer, Berlin

Fong Wang

Pfizer, South San Francisco, CA

Karim Fizazi

Centre Oscar Lambret, University of Paris-Saclay, Lille, France